Clinical Trials Logo
  1. Home
  2. Amphetamine-related Disorders
  3. NCT00000322
  4. Details
NCT00000322 Clinical Trial

Tyrosine for Methamphetamine Dependence - 1

Amphetamine-Related Disorders Clinical Trial

Official title:
Tyrosine for Methamphetamine Dependence

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00000322
Other study ID # NIDA-10739-1
Secondary ID R01-10739-1
Status Completed
Phase Phase 2
First received September 20, 1999
Last updated January 11, 2017
Start date April 1997
Est. completion date December 2001

Study information
Verified date April 1997
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."

Description:

Evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment and craving.

Recruitment information / eligibility
Status Completed
Enrollment 89
Est. completion date December 2001
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.

Exclusion Criteria:

No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Behavioral:
• Tyrosine

Locations
Country Name City State
United States Haight Ashbury Free Clinics San Francisco California

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Craving
Primary Drug use
Primary Retention
Primary Functioning
See also
  Status Clinical Trial Phase
Completed NCT02232789 - Abuse Liability and Human Pharmacology of Mephedrone Phase 1
Completed NCT01449565 - Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Phase 2
Completed NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Phase 2
Active, not recruiting NCT00100074 - To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Phase 1
Active, not recruiting NCT00033072 - Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Phase 1
Recruiting NCT06145698 - Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Recruiting NCT01899313 - A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence N/A
Active, not recruiting NCT00265278 - Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1 Phase 1
Active, not recruiting NCT00000350 - Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Phase 1
Active, not recruiting NCT00089440 - Assessment of Interactions Between Methamphetamine and Aripiprazole - 1 Phase 1
Active, not recruiting NCT00040040 - Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1 Phase 1
Completed NCT00040053 - Ondansetron for the Treatment of Methamphetamine Dependence - 1 Phase 2
Completed NCT00895804 - Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Phase 1
Recruiting NCT03902405 - Computerized Exercise to Alter Stimulant Approach Responses N/A
Recruiting NCT04982796 - Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Phase 1/Phase 2
Completed NCT01386177 - Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT01136278 - Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT00069251 - Bupropion for the Treatment of Methamphetamine Dependence - 1 Phase 2